Medical Cannabis for Tourette's Syndrome in the UK

Introduction

Tourette's Syndrome (TS) is a neurological condition characterised by repetitive, involuntary movements and vocalisations called tics. It affects approximately 300,000 people in the UK, with symptoms typically beginning in childhood and often persisting into adulthood. While many people with Tourette's manage their symptoms without medication, a significant proportion experience tics severe enough to cause significant distress, social impairment, and reduced quality of life.

Conventional pharmacological treatments for Tourette's — including antipsychotics such as haloperidol and risperidone, and alpha-2 agonists such as clonidine — are often poorly tolerated, with significant side effect profiles. It is in this context that medical cannabis has attracted growing interest as a treatment option.

The Evidence Base

The evidence for medical cannabis in Tourette's Syndrome is among the most specific and well-established of any neurological indication. Key studies include:

• A 2003 randomised controlled trial published in the Journal of Clinical Psychiatry found that a single dose of THC significantly reduced tic severity compared to placebo in adult patients with Tourette's.

• A 2017 review of the literature concluded that THC is the most promising pharmacological treatment for Tourette's after conventional options have failed, based on consistent evidence from multiple small trials.

• Data from the UK Medical Cannabis Registry shows that TS patients prescribed CBMPs reported significant improvements in tic severity, anxiety, and quality of life.

The proposed mechanism involves the endocannabinoid system's role in regulating the cortico-striato-thalamo-cortical circuits that are implicated in tic generation. THC appears to modulate dopamine release in the striatum, potentially reducing the urge to tic.

In 2023, a BBC documentary featured a UK patient with Tourette's who had been spending thousands of pounds annually on medical cannabis, calling on the government to make it available on the NHS. His case highlighted both the effectiveness of cannabis for some TS patients and the financial burden of private prescriptions.

Who May Be Eligible?

Medical cannabis for Tourette's Syndrome is typically considered in the UK when:

• The patient has a confirmed TS diagnosis

• Tics are causing significant distress or functional impairment

• At least two conventional pharmacological treatments have been tried and have either failed or caused intolerable side effects

• A specialist neurologist or psychiatrist is satisfied that the benefits outweigh the risks

What Products Are Typically Prescribed?

For Tourette's, UK clinicians most commonly prescribe:

• THC-dominant products — given the specific evidence for THC in tic suppression

• Balanced THC:CBD products — for patients where co-occurring anxiety or OCD symptoms are prominent

• Dronabinol (synthetic THC) — in some cases, where a more standardised THC dose is preferred

Accessing a Prescription

CPGUK can provide free guidance on whether medical cannabis may be appropriate for your Tourette's symptoms and how to access a specialist consultation. The process involves an initial consultation with a neurologist or psychiatrist at a private medical cannabis clinic, an eligibility assessment, and — if approved — a prescription dispensed by a licensed pharmacy.

Important Considerations

• Age — for children and young people with Tourette's, prescribing criteria are stricter and paediatric specialist involvement is required

• Driving — THC-containing products impair driving ability. Patients should not drive after consuming THC

• Mental health history — THC is generally contraindicated in patients with a personal or family history of psychosis

Conclusion

Medical cannabis, particularly THC-dominant products, has a stronger evidence base for Tourette's Syndrome than for many other neurological conditions. For UK patients whose tics have not responded to conventional treatments, it represents a legitimate and legal option. CPGUK is here to help you navigate the process.